Actual 5-year survival of patients with stage IIIB breast carcinoma: Phase II trial of methotrexate, vinblastine, adriamycin, cisplatin, and folinic acid

Stefan Madajewicz, Daniele Matei, Patricia Hentschel, Andrzej Kudelka, William Abel, John J. Fiore, Noshir A. DaCosta, Lakshmi Pendyala

Research output: Contribution to journalArticle

6 Scopus citations


Patients with stage IIIB breast carcinoma represent only a small proportion of women with breast cancer in western countries but may constitute up to 50% of cases in underdeveloped countries. The prognosis remains poor despite aggressive treatment. Nineteen patients (11 with inflammatory breast carcinoma) received at least three courses of neoadjuvant chemotherapy of methotrexate, vinblastine, adriamycin, cisplatin, and folinic acid (MVAC/FA) followed by mastectomy. Six months of cyclophosphamide, methotrexate, and 5-fluorouracil were given after surgery. Radiation therapy followed chemotherapy. Seventy percent of patients achieved complete and 14% partial response after MVAC/FA chemotherapy alone. Eleven patients (58%) survived 5 years, and 30% survived at least 8 years. The addition of cisplatin in combination chemotherapy used as first-line treatment for stage IIIB breast carcinoma was well tolerated, resulted in higher response rates, and appeared to have an effect on overall survival.

Original languageEnglish (US)
Pages (from-to)463-467
Number of pages5
JournalCancer Investigation
Issue number7
StatePublished - Jan 1 1999


ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this